REVIEW

Role of tau in Alzheimer’s dementia and other neurodegenerative diseases

Amita Quadros¹,², Ophelia Inez Weeks², Ghania Ait-Ghezala¹,²

¹Roskamp Institute, Sarasota, Florida, U.S.A.
²Department of Biological Sciences, Florida International University, Miami, Florida, U.S.A.

Summary

Alzheimer’s disease (AD) is defined histopathologically by beta-amyloid (Aβ) senile plaques and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau. The question as to which of these lesions takes precedence in AD pathology has long been an issue of debate. The amyloid cascade hypothesis, currently the predominant hypothesis, considers Aβ peptide to be responsible for the major neurodegeneration observed in AD while the cytoskeleton hypothesis states that tau hyperphosphorylation and subsequent aggregation may be central to the neurodegeneration observed in AD. This review focuses on tau mutations, phosphorylation sites, tau isoforms and the neurohistopathology of AD, and three other tauopathies to demonstrate that disease progression and neuronal loss in AD correlate also with pathological tau and not just amyloid deposition. Although tau is at the center of all these neurodegenerative diseases, there exist differences in morphology, isoforms, phosphorylation sites and mutations in each of these tauopathies. The tauopathies discussed in this review are AD, progressive supranuclear palsy, Pick’s disease, and frontotemporal dementia and Parkinsonism linked to chromosome 17.

Keywords: tauopathies – progressive supranuclear palsy – Pick’s disease – frontotemporal dementia – Parkinsonism

INTRODUCTION

Weingarten and colleagues first discovered a microtubule-associated protein tau (MAPT) in 1975 (Weingarten et al. 1975). Tau in the central nervous system (CNS) is found predominantly in axons of neurons, to a smaller extent in cell bodies and to an even lesser extent in dendrites (Binder et al. 1985, Papasozomenos and Binder 1987). Tau is also present in glial cells although generally under pathological conditions (Berry et al. 2001). The major function of tau in the CNS is in the stabilization of microtubules in neurons and tau might be involved in the establishment and maintenance of neuronal polarity. The C-terminus of tau binds to axonal microtubules while the N-terminus binds to neural plasma membrane components suggesting that tau functions as a linker protein between both. Besides this, tau is also involved in various signal transduction pathways where tau binds with non-receptor src family tyrosine kinases and influences neurite

Amita Quadros, Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL-34243, U.S.A.
aquadros@rfdn.org
941-752-2949
941-752-2948
growth and the motility of microtubules in response to extracellular signals (Buee et al. 2000). However, all of these functions of tau are dependent on its ability to be phosphorylated at site-specific epitopes.

The tau gene located on human chromosome 17q21 in the human genome, contains 16 exons with the major tau isoform being encoded by 11 exons (Goedert et al. 1989, Spillantini and Goedert 1998). Alternative pre-mRNA splicing of exons 2, 3 and 10 in the single tau gene results in the formation of six different isoforms in the adult human brain (Buee et al. 2000). These isoforms ranging from 352-441 amino acids are responsible for the modulation of tau function and are characterized by the presence of three (3R tau) or four (4R tau) tandem repeats of 31-32 amino acids located in the carboxy terminal end which is also the microtubule binding domain of tau (Goedert et al. 1989). These tandem repeats of 3R and 4R are encoded by exons 9-12 (exon 10 inclusion results in the generation of 4R tau while its exclusion generates 3R tau). In the adult human brain the ratio of 3R tau to 4R tau is approximately 1 and this balance is disrupted in the case of tau mutations associated with exon 10 (Goedert and Jakés 2005, D’Souza and Schellenberg 2005). In the N-terminal region there is a presence/absence of a 29 or 58 amino acid insert (exon 2 alone or exons 2 and 3 together), respectively. This N-terminal insert is the major factor responsible for variability in the six isoforms (Buee et al. 2000). In the foetal human brain, exons 2, 3 and 10 are excluded and a single isoform is produced comprised of 316 amino acids (D’Souza and Schellenberg 2005). Foetal tau in the CNS is more highly phosphorylated than tau in the adult brain.

Various kinases and phosphatases are involved in the regulation of tau phosphorylation that occurs at a number of serine, threonine and proline residues (Butler and Shelanski 1986, Ferrer et al. 2005). Tau hyperphosphorylation is at the crux of most tauopathies since hyperphosphorylation dissociates tau from microtubules, destabilizes them and forms paired helical filaments (PHF) in vitro (Lindwall and Cole 1984, Alonso et al. 1994). Tau phosphorylation is regulated by an exquisite equilibrium between kinase and phosphatase activities. An imbalance of these two enzymatic processes can result in abnormal hyperphosphorylation of tau and the generation of PHF. Mutations in the tau gene and tau hyperphosphorylation have been observed in many neurodegenerative diseases as well as in senescent brains. Neurodegenerative diseases of note include Pick’s disease, AD, frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), progressive supranuclear palsy (PSP), corticobasal degeneration, Niemann Pick’s disease, etc. These diseases are all referred to as tauopathies since they all share a common pathology which is aggregated tau. This review focuses on four disorders, since each differs substantially in their tau pathology, especially with respect to AD.

**ALZHEIMER’S DISEASE (AD)**

AD is named after Dr. Alois Alzheimer, a German physician who observed changes in the brain tissue of a woman in 1906 (Moller and Graber 1998). To date, the cause and progression of sporadic AD have not been fully elucidated. AD is neuropathologically characterized by the presence of extracellular amyloid deposits and intracellular NFTs composed of hyperphosphorylated tau. NFTs are preferentially observed in hippocampal cells and the entorhinal cortex. In addition, many cortical and sub-cortical areas such as the amygdala and dorsal raphe nucleus are affected also by NFT formation. Symptoms of the disease include memory loss followed by aphasia, agnosia, apraxia and behavioral disturbances. The disease generally affects people over 65 years of age.

The autosomal-dominant inherited forms of early-onset Alzheimer's disease are caused by mutations in the genes encoding the amyloid precursor protein (APP), presenilin 1 (PS-1) on chromosome 14, and presenilin 2 (PS-2) on chromosome 1 (Buee et al. 2000). A polymorphism in the apolipoprotein E gene (the E4 allele) is also a genetic risk factor associated with late-onset AD (Wilhelmus et al. 2005). Studies supporting the amyloid cascade hypothesis suggest that amyloid is upstream of tau and could be a significant factor in hyperphosphorylating tau, resulting in the formation of neurofibrillary tangles followed by neurodegeneration (Hardy and Selkoe 2002). This theory is supported by various transgenic mouse models of AD that have been studied in the recent past to monitor effects of amyloid beta peptide (Aβ) and tau on cognition and memory deficits, in an attempt to mimic human AD neuropathology of plaques and tangles (Gotz et al. 2001). In the triple transgenic mice with APP, PS-1 and P301L mutations, intracerebral injection with anti-Aβ antibodies decreased tau pathology in younger mice further supporting the claim that Aβ could be upstream of tau (Oddo et al. 2004). However, other studies in transgenic mice have demonstrated MAPT mutations in combination with APP mutations show more neurodegeneration as opposed to APP mutations alone (Lewis et al. 2001).

Immunoblotting of AD tau proteins isolated from aggregated PHF’s reveals the presence of a major tau triplet (tau 55, 64 and 69 kd) and an additional minor 72-74 kd component in the case of AD thereby differentiating it from the other
tauopathies (Mailliot et al. 2000). Also via immunoassay techniques, pathologic tau with distinctive morphology and specificity to AD can be detected. Tau hyperphosphorylation in AD results in the reduced ability of tau to bind to microtubules. Hyperphosphorylation of tau in AD generates differences that can be visualized by phosphorylation-dependent antibodies that include AT100, AP422, 988, TG3 and PHF-27 (Augustinack et al. 2002a).

In AD, tau is hyperphosphorylated at 30 specific amino acid sequences throughout its 441 amino acids (Gong et al. 2005). In vitro studies suggest that increases in Aβ production may potentiate tau phosphorylation by activation of kinases such as glycogen synthase kinase-3 (GSK-3) (Alvarez et al. 1999). Phosphorylated tau protein at T231 is seen in the postmortem brain tissue of patients with AD and can be detected in cerebrospinal fluid (Buerger et al. 2002). Additional studies indicate that increased activation of the stress related kinases JNK and p38 occurs very early in the disease and might be involved in the intraneuronal protein phosphorylation/dephosphorylation imbalance that leads to neurofibrillary degeneration in AD (Reynolds et al. 2000, Pei et al. 2001). It is noteworthy that p35/Cdk5 kinase complex can phosphorylate human tau at seven sites S195, S202, T205, T231, S235, S396 and S404 (Paudel et al. 1993). Also, in vitro studies show increased levels of p25, an activator of cdk5 that phosphorylates tau at S199, S202, and T205 (Augustinack et al. 2002b). And, immunoblotting studies using anti-pS208 and anti-pS210 show that tau-tubulin kinase phosphorylates S208 and S210 in PHF-tau (Tomizawa et al. 2001).

The phosphorylation sites and immunohistochemistry of tau in AD differentiate it from the other tauopathies. In addition, there are no known mutations in tau that are associated with AD as opposed to the other tauopathies (Gotz et al. 2006). Although Gerstmann-Straussler-Scheinker disease (GSS), a prion disease has amyloid plaques as a result of pathological prions they differ in tau pathology from AD morphologically and also with respect to differences in tau isoforms and by immunohistochemistry. In contrast to AD, GSS shows low levels of the major tau triplet (tau 55, 64 and 69 kd) (Mailliot et al. 2000).

PROGRESSIVE SUPRANUCLEAR PALSY (PSP)

PSP, the second most frequent cause of degenerative Parkinsonism was identified by Clifford Richardson, Steele and Olszewski in 1964 (Steele et al. 1964). Neuropathologically, PSP is characterized by abundant neurofibrillary tangles that are primarily localized to subcortical regions and are found in both neurons and glia. Clinical phenotypes of PSP are similar to Parkinson’s disease and include unsteady gait, stiff movements and mild dementia due to a selective loss of caudal intralaminar nuclei that result in the loss of dopaminergic neurons in the substantia nigra (Henderson et al. 2000). Other symptoms include blurred vision, downward gaze palsy, followed by depression, sleeplessness, memory loss, dysphagia and dysarthria. Men are more prone to this disease than women and the age of onset varies from the early forties to late eighties.

The etiology of this disease is not fully understood but data implicate polymorphisms in the tau gene as a risk factor. Conrad et al. (1997) first identified a dinucleotide polymorphism involving a TG repeat in intron 9. The TG repeat of 11 dinucleotides is termed the A0 allele, while the A1, A2, A3 and A4 alleles represent 12, 13, 14 and 15 dinucleotide repeats, respectively. Subsequent studies have shown that this polymorphism is inherited as part of two extended haplotypes (H1 and H2) that cover the entire tau gene (Baker et al. 1999). The A0, A1 and A2 alleles are present in haplotype H1 while A3 and A4 are part of haplotype H2. However, these polymorphisms are not specific to PSP because A0 allele and H1 haplotype are also implicated in corticobasal degeneration (Houlden et al. 2001). Mutations in the tau gene associated with neuropathology typical of PSP include a silent mutation S305S in exon 10, a R5L in exon 1, and G303V mutation in exon 10 (Stanford et al. 2000, Poorkaj et al. 2002, Ros et al. 2005a) (Table 1). All of the above mutations result in the predominant tau isoform being 4R tau. The deletion of asparagine at codon 296 (del296) of the tau gene causes atypical PSP in patients homozygous for this mutation while the heterozygous mutation phenotypically resembles Parkinson’s disease (Grover et al. 2002). The S352L homozygous tau gene mutation found in two English siblings showed tau neuropathology different from FTDP-17 cases and functional studies showed reduced microtubule assembly and increased aggregation of tau. Both siblings carried the H1/H1 haplotype associated with PSP (Nicholl et al. 2003). In addition to mutations in the tau gene, studies have also shown linkage of PSP to a new locus 1q31.1 in chromosome 1 (Ros et al. 2005b).

Pathological and biochemical studies in PSP brains have shown a predominance of hyperphosphorylated aggregated 4R tau isoforms (Litvan and Hutton 1998). Tau pathology in the postmortem PSP brain may include neuropil threads, neuritic plaques, tufted astrocytes and glial inclusions, as well as microglia and globule tangles (Morris et al. 2002). Ultrastructural analyses have revealed differences in AD and PSP pathology. Tau
morphology in AD is PHFs whereas the tau filaments are straight in PSP (Spillantini and Goedert 1998, Morris et al. 2002). In addition, electrophoretic profiles of aggregated tau proteins in PSP differ from that of AD. In AD all six isoforms of tau are phosphorylated and the aggregated tau, as detected by immunoblotting appears as a major tau triplet (tau 55, 64 and 69 kd) while in PSP only the 4R isoforms are phosphorylated and appear as a major tau doublet (tau 55 and 64 kd) (Mailliot et al. 2000).

The kinases that may cause hyperphosphorylation of tau in PSP are phospho-p38 MAPK, and the stress kinases SAPK/JNK-P which are upregulated in neurons, astrocytes and oligodendroglia displaying aggregated tau (Ferrer et al. 2001). Another kinase that is implicated in abnormal phosphorylation of tau in PSP is casein kinase 1 delta (Schwab et al. 2000).

**PICK’S DISEASE**

Arnold Pick first described Pick’s disease in 1892 (Karenberg 2001). Pick’s disease differs from AD in several aspects. It is marked by rounded microscopic structures called Pick’s bodies rather than the plaques and tangles of AD. Pick’s disease is characterized by frontotemporal lobar atrophy, gliosis and ballooned neurons. The first symptoms associated with this disease are personality changes, poor social judgement, difficulty with language and poor attention span. The onset is usually at 40 years of age and is less common after 60 years of age.

Pick’s disease is also referred to as one of the fronto-temporal dementias (FTDs) caused by mutations in the tau gene in exons 9, 12, 11 and 13 (Murrell et al. 1999, Yen et al. 1999, Rizzini et al. 2000, Pickering-Brown et al. 2000, Neumann et al. 2001, Rosso et al. 2002, Hogg et al. 2003, Bronner et al. 2005) (Table 1). All mutations associated with Pick’s disease and identified in table 1 show a reduced microtubule assembly of tau. Functional analysis of tau with G389R and K257T mutations have demonstrated increased susceptibility of tau to calpain I digestion (a feature probably related to the formation of a Pick’s disease type of histology) in addition to reduced microtubule assembly of tau (Pickering-Brown et al. 2000). Besides mutations in the tau gene, a novel mutation G183V in the presenilin-1 (PS-1) gene affects the splice signal at the junction of the sixth exon and intron resulting in clinical manifestations similar to Pick-type tauopathy, in the absence of extracellular beta-amyloid deposits (Dermaut et al. 2004). Subsequent studies showed that a mutation in PS-1, M146L which accounts for most cases of familial AD can also cause Pick’s disease (Halliday et al. 2005). PS-1 mutations are known to enhance gamma-secretase activity resulting in an increase in Aβ42 (Haass and De Strooper 1999). However, PS-1 mutations in addition to increasing Aβ42 also increase the production of total tau proteins (Shepherd et al. 2004). The mechanism of action of M146L mutation is hypothesized to predispose the person to Pick’s disease, or AD, or both, by affecting multiple intracellular pathways involved with tau phosphorylation, resulting in 3R isoforms and amyloid metabolism (Halliday et al. 2005).

Histopathologically, Pick’s bodies are intraneuronal inclusions of tau, and only phosphorylated 3R-tau isoforms aggregate into filaments. They are characterized as a major tau doublet (tau 55 and 64 kd) (Mailliot et al. 2000). However, studies have also revealed 4R aggregated tau isoforms in patients with sporadic Pick’s disease, although the 3R isoforms are more predominant (Zhukareva et al. 2002). Interestingly, analysis of dephosphorylated tau from the brain of a patient with the G389R mutation revealed a prominent tau band with 4R isoforms and no amino terminal inserts (Murrell et al. 1999). Ultrastructurally, Pick’s bodies consist of both random coiled and straight filaments. Further, aggregated tau proteins in Pick’s disease are not detected by the monoclonal antibody 12E8 that binds to phosphorylated Ser262/356 residues, as is the case with other neurodegenerative diseases. This lack of 12E8 immunoreactivity suggests either a kinase inhibition in neurons that degenerate in Pick’s disease or an absence of the related kinases (Probst et al. 1996). Furthermore, the active stress kinase p38 has been shown to enhance abnormal tau phosphorylation in Pick’s disease (Puig et al. 2004). The other kinases implicated in Pick’s disease are similar to those involved in PSP.

**FRONTOTEMPORAL DEMENTIA AND PARKINSONISM LINKED TO CHROMOSOME 17 (FTDP-17)**

The name frontotemporal dementia was first proposed by the Lund and Manchester group in 1994 (Mori 2004). Wilhelmsen and colleagues renamed FTD as FTDP-17 after observing clinical and pathological features of frontotemporal dementia in patients with genetic defects in chromosome 17q21-22 (Buee et al. 2000). FTDP-17 is characterized by behavioural, cognitive and motor disturbances that are caused by lesions in the frontotemporal regions of the brain. The pattern of inheritance in FTDP-17 is autosomal dominant with an early age of onset between 45-65 years of age. Pathological changes in the brain include frontotemporal atrophy with neuronal loss, gray and white matter gliosis and superficial cortical spongiform.
### Table 1. Tau mutations on chromosome 17

<table>
<thead>
<tr>
<th>Mutations</th>
<th>Exon location</th>
<th>Pathogenic effects of Tau mutations</th>
<th>Disease Pathology</th>
<th>Literature cited</th>
</tr>
</thead>
<tbody>
<tr>
<td>R5H</td>
<td>1</td>
<td>Increased aggregation of tau protein, reduced MT assembly and all six isoforms affected</td>
<td>AD-like</td>
<td>Hayashi et al. 2002, D’Souza and Schellenberg 2005</td>
</tr>
<tr>
<td>R5L</td>
<td>1</td>
<td>Increased aggregation of tau protein, reduced MT assembly and all six tau isoforms affected</td>
<td>PSP</td>
<td>Poorkaj et al. 2002</td>
</tr>
<tr>
<td>K257T</td>
<td>9</td>
<td>Increased aggregation of tau protein, reduced MT assembly and all six tau isoforms affected</td>
<td>Pick’s disease</td>
<td>Rizzini et al. 2000</td>
</tr>
<tr>
<td>I260V</td>
<td>9</td>
<td>Increased aggregation of tau protein, reduced MT assembly and all six tau isoforms affected</td>
<td>FTDP-17</td>
<td>Brandt et al. 2005</td>
</tr>
<tr>
<td>L266V</td>
<td>9</td>
<td>Increased aggregation of tau protein, reduced MT binding and all six tau isoforms affected, increases splicing of exon 10</td>
<td>Pick’s disease</td>
<td>Hogg et al. 2003, D’Souza and Schellenberg 2005</td>
</tr>
<tr>
<td>N279K</td>
<td>10</td>
<td>Increased splicing of exon 10 changing 4R:3R ratio</td>
<td>FTDP-17, FTDP-17</td>
<td>Sergeant et al. 2005, D’Souza and Schellenberg 2005</td>
</tr>
<tr>
<td>delK280</td>
<td>10</td>
<td>Increased aggregation of tau protein, decreases splicing of exon 10, reduced MT assembly</td>
<td>FTDP-17</td>
<td>Brandt et al. 2005</td>
</tr>
<tr>
<td>L284L</td>
<td>10</td>
<td>Increase splicing of exon 10 changing 4R:3R ratio</td>
<td>AD-like</td>
<td>D’Souza and Schellenberg 2005</td>
</tr>
<tr>
<td>N296H</td>
<td>10</td>
<td>Increases splicing of exon 10, increases tau aggregation and reduces tau promoted tubulin polymerization</td>
<td>FTDP-17</td>
<td>Grover et al. 2002</td>
</tr>
<tr>
<td>N296N</td>
<td>10</td>
<td>Increases splicing of exon 10 thereby increasing ratio of 4R/3R tau</td>
<td>FTD</td>
<td>Grover et al. 2002</td>
</tr>
<tr>
<td>P301L</td>
<td>10</td>
<td>Increased aggregation of tau protein, does not affect splicing of exon 10, reduced MT binding, 4R tau isoforms</td>
<td>FTDP-17</td>
<td>Hutton et al. 1998</td>
</tr>
<tr>
<td>P301S</td>
<td>10</td>
<td>Increased aggregation of tau protein, does not affect splicing of exon 10, reduced MT binding</td>
<td>FTDP-17</td>
<td>Sergeant et al. 2005</td>
</tr>
<tr>
<td>G303V</td>
<td>10</td>
<td>Increases splicing of exon 10 increasing 4R:3R ratio</td>
<td>PSP</td>
<td>Ros et al. 2005a</td>
</tr>
<tr>
<td>S305N</td>
<td>10</td>
<td>Increase microtubule assembly, increases splicing of exon 10 increasing 4R:3R ratio</td>
<td>Pick’s disease</td>
<td>Sergeant et al. 2005, D’Souza and Schellenberg 2005</td>
</tr>
<tr>
<td>S305S</td>
<td>10</td>
<td>Increase splicing of exon 10 increasing 4R:3R ratio</td>
<td>PSP</td>
<td>Stanford et al. 2000</td>
</tr>
<tr>
<td>L315R</td>
<td>11</td>
<td>Reduced MT assembly</td>
<td>Pick’s/FTDP-17</td>
<td>Brandt et al. 2005</td>
</tr>
<tr>
<td>K317M</td>
<td>11</td>
<td>Reduced MT assembly</td>
<td>Pick’s disease pathology</td>
<td>Zarranz et al. 2005</td>
</tr>
<tr>
<td>S320F</td>
<td>11</td>
<td>Reduced MT assembly</td>
<td>Pick’s disease pathology</td>
<td>Rosso et al. 2002, Brandt et al. 2005</td>
</tr>
<tr>
<td>Q336R</td>
<td>12</td>
<td>Increase microtubule assembly, increased aggregation of tau protein</td>
<td>Pick’s disease pathology</td>
<td>Pickering-Brown et al. 2004</td>
</tr>
<tr>
<td>V337M</td>
<td>12</td>
<td>Increased aggregation of tau protein, reduced MT binding</td>
<td>AD-like</td>
<td>Poorkaj et al. 1998</td>
</tr>
</tbody>
</table>
Continued Table 1

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Most of the known mutations causing FTDP-17 occur in the C-terminal end of tau and affect mainly exons 9-12 that encode the microtubule binding repeats. The different tau mutations give rise to different pathological characteristics depending on their location. Missense mutations outside exon 10 result in the formation of straight neuronal filaments in all six isoforms. These filaments resemble the PHFs observed in AD. In contrast, missense or splice mutations that directly affect exon 10 result in both neuronal and glial tau pathology with filaments consisting predominantly of 4R tau isoforms (van Slegtenhorst et al. 2000).

Tau mutations causing FTDP-17 either alter the ratio of 4R:3R tau through faulty splicing of exon 10 or directly impair the binding of tau to microtubules and its subsequent aggregation properties. FTDP-17 mutations affecting exon 10 are presented in Table 1. The intronic mutations in the 5′ splice site of exon10 are E10+3, E10+11, E10+12, E10+13, E10+14, E10+16, E10+33, E10+19, E10+29 (Hutton et al. 1998, van Slegtenhorst et al. 2000, Mack et al. 2001, Morris et al. 2003, Sergeant et al. 2005). Exon 10 and intronic mutations following exon 10 affect the cellular functioning and biochemical expression of tau by changing the normal 1:1 ratio of 3R:4R isoforms. Most of the intronic mutations increase splicing of exon 10 except E10+19 and E10+29 (which decrease the splicing of exon 10) and result in the predominant tau isoform being 4R. Mutations affecting exon 10 cause ribbon twisted filaments of mostly 4R tau that do not bind to microtubules. Mutations outside of exon 10 result in PHF and straight filaments generally affecting all 6 isoforms that do not bind to microtubules. (Sergeant et al. 2005). Most of these mutations alter the ability of tau to interact with microtubules thereby increasing the likelihood that tau will assemble into filaments (Brandt et al. 2005). However, other mutations like delN296, N296N and N296H reduce the ability of tau to promote assembly of microtubules, without having a significant effect on tau filament formation (Yoshida et al. 2002).

Other mutations involved with FTDP-17 include a R5H mutation in exon 1 which reduces microtubule assembly and promotes formation of fibrils in vitro, a T427M mutation in exon 13 identified in an Italian patient with a family history of FTD, and the E342V mutation in exon 12 which preferentially increases 4R tau (Hayashi et al. 2002, Giaccone et al. 2005, Lippa et al. 2000 respectively). The Q336R mutation in exon 12 of the tau gene increases microtubule assembly of tau in vitro while an adjacent mutation V337M decreases microtubule assembly of tau (Pickering-Brown et al. 2004). The tau pathology associated with these two different mutations although adjacent to each other is also different. The former mutation results in Pick-type tau histology while the latter has NFTs similar to AD, like tau pathology (Pookraj et al. 1998, Pickering-Brown et al. 2004). Another mutation implicated in FTDP-17 is the K317M mutation located in exon 11 of the MAPT gene. Biochemical analysis of brain homogenates revealed two bands of phospho-tau at 64 and 68 kd (Zarranz et al. 2005). However, there have been many cases of familial FTDP-17 with no detectable mutations in the tau gene. Recent studies have shown that these cases of familial FTDP-17 are caused by mutations in the progranulin gene situated just next to the tau gene (Baker et al. 2006, Cruts et al. 2006).

Studies on FTDP-17 mutations expressed in differentiated neuronal cells reveal decreased phosphorylation of pathologically relevant S202/T205 sites, but phosphorylation at the S396/S404 site is moderately decreased for all mutant isoforms (Furukawa et al. 2003). Other studies suggest that mutations in tau that decrease its microtubule-binding capacity augment calcium influx by depolymerizing microtubules and activating adenyl cyclase and protein kinase A (Buee-Scherrer et al. 2002). Transgenic mouse models with the different mutations of tau have been developed to study the effects of tau pathology on cognition and memory. Some of these mouse models have been successful in mimicking the molecular and cellular features of the human...
DISCUSSION

Tau, a microtubule-associated protein, is abnormally hyperphosphorylated in senescent tissue and in a number of neurodegenerative diseases collectively referred to as tauopathies. There is no known cure to date for each of the tauopathies discussed in this review. All available therapies provide only symptomatic relief. The key challenge facing scientists in the area of neurodegenerative diseases is the need to develop effective therapeutic agents that could lead to a cure for these diseases.

Tau is a substrate for various protein kinases in vitro, namely, the Ca++/Calmodulin dependent protein kinase II, Casein kinase II, GSK3, the MAPK, also known as ERK, cdk5 and the microtubule affinity regulating kinase (MARK). The stress activated protein kinases SAPK3/p38gamma and SAPK4/p38delta also cause abnormal hyperphosphorylation of tau (Buee-Scherrer et al. 2002). Each kinase phosphorylates different residues that are proline or non-proline specific. GSK3 phosphorylates S199 but not detectably S202 or T205. The MAPks may not be strictly proline specific: p38 phosphorylates the nonproline sites S185, T245, S305, and S356. The MAPks and GSK3 are important tau kinases that may be involved in the pathogenic hyperphosphorylation of tau in AD (Paudel et al. 1993). Phosphorylated tau is dephosphorylated by numerous protein phosphatases in vitro. Phosphatase 1, phosphatase 2A and the Ca++/calmodulin-dependent phosphatase, phosphatase 2B all have been shown to dephosphorylate tau (Gong et al. 1994a, Gong et al. 1994b). Dephosphorylation of tau by these phosphatases increases the ability of tau to bind to microtubules and also promotes microtubule assembly.

In vitro models used to verify these results are PC12 cells and SH-SY5Y neuroblastoma cells.

Table 2. Summary of the tauopathies

<table>
<thead>
<tr>
<th>Disease</th>
<th>Tau repeats</th>
<th>Age of onset (years)</th>
<th>Literature cited</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pick’s</td>
<td>3 repeat</td>
<td>40-60</td>
<td>Pickering-Brown et al. 2004, Mailliot et al. 2000</td>
</tr>
<tr>
<td>PSP</td>
<td>4 repeat</td>
<td>Early 40 - late 80</td>
<td>Mailliot et al. 2000, Morris et al. 2003</td>
</tr>
<tr>
<td>AD</td>
<td>3 repeat + 4 repeat</td>
<td>Over 65</td>
<td>Mailliot et al. 2000, Gotz et al. 2006</td>
</tr>
<tr>
<td>FTDP-17</td>
<td>3 repeat + 4 repeat</td>
<td>45 -65</td>
<td>Mailliot et al. 2000, Pickering-Brown et al. 2004</td>
</tr>
</tbody>
</table>

However, it is also important to mention at this stage that tau hyperphosphorylation alone is not the predisposing factor for all these tauopathies. Other factors like oxidative stress, enzyme regulation, cellular vulnerability and genetic mutations also play a major role in the pathogenicity of tauopathies. Although mutations in PS-1 account for the majority of familial cases of AD and cause an increased production of Aβ42, little is known about the role of tau in PS-1 AD. There is a 6-fold increase in tau-2-positive plaques in PS-1 cases thereby suggesting that PS-1 mutations increase tau hyperphosphorylation perhaps by increasing Aβ, which in turn activates GSK-3 (Shepherd et al. 2004). This theory supports the amyloid cascade hypothesis of amyloid being upstream of tau in AD.

Various transgenic mice have been developed to study the effects of tau mutations and the various kinases and phosphatases on tau, and to monitor the neuropathology in vivo. There has been some success in the latter with the development of transgenic mice expressing wild type tau and mutant tau P301L (Lewis et al. 2000). Other transgenic mouse models have included glial pathology in addition to neuronal pathology (Higuchi et al. 2002). Although transgenic mice with the mutant V337M mutation are said to show behavioral and pathological features similar to AD (Tanemura et al. 2002), they still do not completely simulate or mimic the conditions in the human brain. The triple transgenic mouse (APP, PS-1 and tau) model shows the closest resemblance of AD pathology in humans with respect to plaques and
tangles (Oddo et al. 2003). Researchers have also tried to mimic human AD pathology in monkeys with a view to finding suitable therapeutic agents to treat the disease. However, the drawback of this model of AD is the extended time period (around 10 years) necessary for Aβ deposition in these primates (Ridley et al. 2006). To further investigate the hypothesis that NFTs are responsible for brain dysfunction and neurodegeneration, transgenic mice expressing mutant tau that could be suppressed with doxycycline were created (Santacruz et al. 2005). These mice showed improved memory function after suppression of human mutant tau but did not prevent the accumulation of NFTs. Also, MAPT mutations along with APP mutations cause more neurodegeneration in AD mouse models than APP mutations alone (Lewis et al. 2001) and studies from human tissue with AD show that NFTs correlate better with impairment than amyloid (Arriagada et al. 1992). Altogether, these results suggest that abnormal tau correlates more with the pathogenesis of AD than amyloid. And, although transgenic mice have allowed considerable progress in our understanding, they still present limitations for modeling human AD. An overview of the different isoforms of tau in various tauopathies including age of onset is presented in Table 2. Both amyloid and tau hypotheses have their strengths and drawbacks and continued efforts should be made in both areas towards finding a cure for AD and other tauopathies.

REFERENCES


Conrad C, Andreadis A, Trojanowski JQ, Dickson DW, Kang D, Chen XH, Wiederholt W, Hansen L, Masliah E, Thal LJ, Katzman R,


